Ribociclib Approved for Advanced Breast Cancer [News in Brief]

The FDA has approved ribociclib combined with aromatase inhibitor therapy for women with metastatic HR-positive, HER2-negative breast cancer. It is the second CDK 4/6 inhibitor approved for these patients, behind palbociclib; a third is under investigation.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: News in Brief Source Type: research